It’s time to celebrate the incredible women leading the way in AI! Nominate your inspiring leaders for VentureBeat’s Women in AI Awards today before June 18. Learn More
Endiatx’s swallowable robotic pill hits clinical trials, company preps for FDA review and commercial launch
In a development straight out of science fiction, Endiatx, a pioneering medical technology company, is making significant strides in bringing its robotic pill to market. The company’s CEO, Torrey Smith, recently sat down with VentureBeat to share exciting updates on their progress, nearly two years after our initial coverage of the startup’s ambitious vision.
Founded in 2019, Endiatx has been steadily working towards realizing the fantastic voyage of miniaturized robots navigating the human body for diagnostic and therapeutic purposes. Their flagship product, the PillBot, is an ingestible robotic capsule equipped with cameras, sensors, and wireless communication capabilities, allowing doctors to examine the gastrointestinal tract with unprecedented precision and control.
In the interview, Smith revealed that Endiatx has raised $7 million in funding to date, with the largest investment of $1.5 million coming from Singapore-based Verge Health Tech Fund. This injection of capital has propelled the company forward, enabling them to refine their technology and conduct clinical trials.
VB Transform 2024 Registration is Open
Join enterprise leaders in San Francisco from July 9 to 11 for our flagship AI event. Connect with peers, explore the opportunities and challenges of Generative AI, and learn how to integrate AI applications into your industry. Register Now
“We’re currently in clinical trials with our pill bot technology,” Smith explained. “We’ll be starting pivotal trials at a leading U.S. medical institution in Q3/Q4.” Though Smith did not name the institution due to confidentiality agreements, he hinted that it is a renowned facility known for its expertise in gastroenterology.
The PillBot has come a long way since its inception. The current prototype measures just 13mm by 30mm and boasts …
Article Attribution | Read More at Article Source
It’s time to celebrate the incredible women leading the way in AI! Nominate your inspiring leaders for VentureBeat’s Women in AI Awards today before June 18. Learn More
Endiatx’s swallowable robotic pill hits clinical trials, company preps for FDA review and commercial launch
In a development straight out of science fiction, Endiatx, a pioneering medical technology company, is making significant strides in bringing its robotic pill to market. The company’s CEO, Torrey Smith, recently sat down with VentureBeat to share exciting updates on their progress, nearly two years after our initial coverage of the startup’s ambitious vision.
Founded in 2019, Endiatx has been steadily working towards realizing the fantastic voyage of miniaturized robots navigating the human body for diagnostic and therapeutic purposes. Their flagship product, the PillBot, is an ingestible robotic capsule equipped with cameras, sensors, and wireless communication capabilities, allowing doctors to examine the gastrointestinal tract with unprecedented precision and control.
In the interview, Smith revealed that Endiatx has raised $7 million in funding to date, with the largest investment of $1.5 million coming from Singapore-based Verge Health Tech Fund. This injection of capital has propelled the company forward, enabling them to refine their technology and conduct clinical trials.
VB Transform 2024 Registration is Open
Join enterprise leaders in San Francisco from July 9 to 11 for our flagship AI event. Connect with peers, explore the opportunities and challenges of Generative AI, and learn how to integrate AI applications into your industry. Register Now
“We’re currently in clinical trials with our pill bot technology,” Smith explained. “We’ll be starting pivotal trials at a leading U.S. medical institution in Q3/Q4.” Though Smith did not name the institution due to confidentiality agreements, he hinted that it is a renowned facility known for its expertise in gastroenterology.
The PillBot has come a long way since its inception. The current prototype measures just 13mm by 30mm and boasts …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]